March 4, 2022Expert Opinion on Drug Metabolism & Toxicology

Incidence of grade 3–4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis

View Full Paper

Ask AI

Bookmark

Abstract

Clinicians should carefully consider these risks, especially taking into account that the use of PARPi in mCRPC patients is expected to rise in the near future.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rizzo et al. (2022) studied this question.

synapsesocial.com/papers/69daa9a43bc1ef7225684819 https://doi.org/10.1080/17425255.2022.2072727

View Full Paper

Ask AI

Bookmark

Abstract

Clinicians should carefully consider these risks, especially taking into account that the use of PARPi in mCRPC patients is expected to rise in the near future.